Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery

Yasuhiko Nakao; Pouya Amrollahi; Gopanandan Parthasarathy; Amy S. Mauer; Tejasav S. Sehrawat; Patrick Vanderboom; K. Sreekumaran Nair; Kazuhiko Nakao; Alina M. Allen; Tony Y. Hu; Harmeet Malhi

doi:10.1016/j.nano.2021.102430

Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery

Yasuhiko Nakao, Pouya Amrollahi, Gopanandan Parthasarathy, Amy S. Mauer, Tejasav S. Sehrawat, Patrick Vanderboom, K. Sreekumaran Nair, Kazuhiko Nakao, Alina M. Allen, Tony Y. Hu, Harmeet Malhi

Research output: Contribution to journal › Article › peer-review

Abstract

There is increasing interest in the development of minimally invasive biomarkers for the diagnosis and prognosis of NAFLD via extracellular vesicles (EV). Plasma EVs were isolated by differential ultracentrifugation and quantified by nanoparticle tracking analysis from pre (n = 28) and post (n = 28) weight loss patients. In the pre weight loss group 22 had NAFLD. Nanoplasmon enhanced scattering (nPES) of gold nanoparticles conjugated to hepatocyte-specific antibodies was employed to identify hepatocyte-specific EVs. Complex lipid panel and targeted sphingolipids were performed. Logistic regression analysis was used to identify predictors of NAFLD. Plasma levels of EVs and hepatocyte-derived EVs are dynamic and decrease following NAFLD resolution due to weight loss surgery. Hepatocyte-derived EVs correlate with steatosis in NAFLD patients and steatosis and inflammation in NASH patients. Plasma levels of small EVs correlate with EV sphingolipids in patients with NASH. Hepatocyte-derived EVs measured by the nPES assay could serve as a point-of-care test for NAFLD.

Original language	English (US)
Article number	102430
Journal	Nanomedicine: Nanotechnology, Biology, and Medicine
Volume	36
DOIs	https://doi.org/10.1016/j.nano.2021.102430
State	Published - Aug 2021

Keywords

Bariatric surgery
Exosome
Fatty liver
Sphingolipid

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Molecular Medicine
Biomedical Engineering
General Materials Science
Pharmaceutical Science

Access to Document

10.1016/j.nano.2021.102430

Cite this

Nakao, Y., Amrollahi, P., Parthasarathy, G., Mauer, A. S., Sehrawat, T. S., Vanderboom, P., Nair, K. S., Nakao, K., Allen, A. M., Hu, T. Y., & Malhi, H. (2021). Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery. Nanomedicine: Nanotechnology, Biology, and Medicine, 36, Article 102430. https://doi.org/10.1016/j.nano.2021.102430

@article{63e6d39f34a34bb3944661a0dbc5b528,

title = "Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery",

abstract = "There is increasing interest in the development of minimally invasive biomarkers for the diagnosis and prognosis of NAFLD via extracellular vesicles (EV). Plasma EVs were isolated by differential ultracentrifugation and quantified by nanoparticle tracking analysis from pre (n = 28) and post (n = 28) weight loss patients. In the pre weight loss group 22 had NAFLD. Nanoplasmon enhanced scattering (nPES) of gold nanoparticles conjugated to hepatocyte-specific antibodies was employed to identify hepatocyte-specific EVs. Complex lipid panel and targeted sphingolipids were performed. Logistic regression analysis was used to identify predictors of NAFLD. Plasma levels of EVs and hepatocyte-derived EVs are dynamic and decrease following NAFLD resolution due to weight loss surgery. Hepatocyte-derived EVs correlate with steatosis in NAFLD patients and steatosis and inflammation in NASH patients. Plasma levels of small EVs correlate with EV sphingolipids in patients with NASH. Hepatocyte-derived EVs measured by the nPES assay could serve as a point-of-care test for NAFLD.",

keywords = "Bariatric surgery, Exosome, Fatty liver, Sphingolipid",

author = "Yasuhiko Nakao and Pouya Amrollahi and Gopanandan Parthasarathy and Mauer, {Amy S.} and Sehrawat, {Tejasav S.} and Patrick Vanderboom and Nair, {K. Sreekumaran} and Kazuhiko Nakao and Allen, {Alina M.} and Hu, {Tony Y.} and Harmeet Malhi",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = aug,

doi = "10.1016/j.nano.2021.102430",

language = "English (US)",

volume = "36",

journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",

issn = "1549-9634",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery

AU - Nakao, Yasuhiko

AU - Amrollahi, Pouya

AU - Parthasarathy, Gopanandan

AU - Mauer, Amy S.

AU - Sehrawat, Tejasav S.

AU - Vanderboom, Patrick

AU - Nair, K. Sreekumaran

AU - Nakao, Kazuhiko

AU - Allen, Alina M.

AU - Hu, Tony Y.

AU - Malhi, Harmeet

PY - 2021/8

Y1 - 2021/8

N2 - There is increasing interest in the development of minimally invasive biomarkers for the diagnosis and prognosis of NAFLD via extracellular vesicles (EV). Plasma EVs were isolated by differential ultracentrifugation and quantified by nanoparticle tracking analysis from pre (n = 28) and post (n = 28) weight loss patients. In the pre weight loss group 22 had NAFLD. Nanoplasmon enhanced scattering (nPES) of gold nanoparticles conjugated to hepatocyte-specific antibodies was employed to identify hepatocyte-specific EVs. Complex lipid panel and targeted sphingolipids were performed. Logistic regression analysis was used to identify predictors of NAFLD. Plasma levels of EVs and hepatocyte-derived EVs are dynamic and decrease following NAFLD resolution due to weight loss surgery. Hepatocyte-derived EVs correlate with steatosis in NAFLD patients and steatosis and inflammation in NASH patients. Plasma levels of small EVs correlate with EV sphingolipids in patients with NASH. Hepatocyte-derived EVs measured by the nPES assay could serve as a point-of-care test for NAFLD.

AB - There is increasing interest in the development of minimally invasive biomarkers for the diagnosis and prognosis of NAFLD via extracellular vesicles (EV). Plasma EVs were isolated by differential ultracentrifugation and quantified by nanoparticle tracking analysis from pre (n = 28) and post (n = 28) weight loss patients. In the pre weight loss group 22 had NAFLD. Nanoplasmon enhanced scattering (nPES) of gold nanoparticles conjugated to hepatocyte-specific antibodies was employed to identify hepatocyte-specific EVs. Complex lipid panel and targeted sphingolipids were performed. Logistic regression analysis was used to identify predictors of NAFLD. Plasma levels of EVs and hepatocyte-derived EVs are dynamic and decrease following NAFLD resolution due to weight loss surgery. Hepatocyte-derived EVs correlate with steatosis in NAFLD patients and steatosis and inflammation in NASH patients. Plasma levels of small EVs correlate with EV sphingolipids in patients with NASH. Hepatocyte-derived EVs measured by the nPES assay could serve as a point-of-care test for NAFLD.

KW - Bariatric surgery

KW - Exosome

KW - Fatty liver

KW - Sphingolipid

UR - http://www.scopus.com/inward/record.url?scp=85110092524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85110092524&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2021.102430

DO - 10.1016/j.nano.2021.102430

M3 - Article

C2 - 34174416

AN - SCOPUS:85110092524

SN - 1549-9634

VL - 36

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

M1 - 102430

ER -

Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this